| The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications A Carnero, C Blanco-Aparicio, O Renner, W Link, JFM Leal Current cancer drug targets 8 (3), 187-198, 2008 | 1054 | 2008 |
| ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage R Maya, M Balass, ST Kim, D Shkedy, JFM Leal, O Shifman, M Moas, ... Genes & development 15 (9), 1067-1077, 2001 | 968 | 2001 |
| Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis TM Gottlieb, JFM Leal, R Seger, Y Taya, M Oren Oncogene 21 (8), 1299-1303, 2002 | 624 | 2002 |
| PTEN, more than the AKT pathway C Blanco-Aparicio, O Renner, JFM Leal, A Carnero Carcinogenesis 28 (7), 1379-1386, 2007 | 553 | 2007 |
| Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead WH Goodson III, L Lowe, DO Carpenter, M Gilbertson, A Manaf Ali, ... Carcinogenesis 36 (Suppl_1), S254-S296, 2015 | 351 | 2015 |
| Excess β-catenin promotes accumulation of transcriptionally active p53 A Damalas, A Ben-Ze'ev, I Simcha, M Shtutman, JFM Leal, J Zhurinsky, ... The EMBO Journal 18 (11), 3054-3063, 1999 | 294 | 1999 |
| Regulation of p53 M Oren, A Damalas, T Gottlieb, D Michael, J Taplick, JF LEAL, R Maya, ... Annals of the New York Academy of Sciences 973 (1), 374-383, 2002 | 261 | 2002 |
| Physical and functional interaction between p53 and the Werner's syndrome protein G Blander, J Kipnis, JFM Leal, CE Yu, GD Schellenberg, M Oren Journal of Biological Chemistry 274 (41), 29463-29469, 1999 | 204 | 1999 |
| RETRACTED ARTICLE: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus D Bernard, JF Martinez-Leal, S Rizzo, D Martinez, D Hudson, T Visakorpi, ... Oncogene 24 (36), 5543-5551, 2005 | 190 | 2005 |
| PM01183, a new DNA minor-grove covalent binder with potent in vitro and in vivo antitumour activity JFM Leal, M Martínez-Díez, V García-Hernández, V Moneo, A Domingo, ... British Journal of Pharmacology 161 (5), 1099-1110, 2010 | 168 | 2010 |
| Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells G Santamaría Nuñez, CMG Robles, C Giraudon, JF Martínez-Leal, ... Molecular cancer therapeutics 15 (10), 2399-2412, 2016 | 143 | 2016 |
| Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma MB Wozniak, R Villuendas, JR Bischoff, CB Aparicio, JFM Leal, ... Haematologica 95 (4), 613, 2010 | 122 | 2010 |
| S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis JF Leal, I Ferrer, C Blanco-Aparicio, J Hernandez-Losa, S Ramon y Cajal, ... Carcinogenesis 29 (11), 2089-2095, 2008 | 114 | 2008 |
| PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma C Gomez-Abad, H Pisonero, C Blanco-Aparicio, G Roncador, ... Blood, The Journal of the American Society of Hematology 118 (20), 5517-5527, 2011 | 106 | 2011 |
| Molecular pharmacology and antitumor activity of Zalypsis® in several human cancer cell lines JFM Leal, V García-Hernández, V Moneo, A Domingo, ... Biochemical pharmacology 78 (2), 162-170, 2009 | 94 | 2009 |
| Translation elongation factor eEF1A2 is a novel anticancer target for the marine natural product plitidepsin A Losada, MJ Muñoz-Alonso, C García, PA Sánchez-Murcia, ... Scientific reports 6 (1), 35100, 2016 | 85 | 2016 |
| Cellular senescence bypass screen identifies new putative tumor suppressor genes JFM Leal, J Fominaya, A Cascon, MV Guijarro, C Blanco-Aparicio, ... Oncogene 27 (14), 1961-1970, 2008 | 83 | 2008 |
| PPP1CA contributes to the senescence program induced by oncogenic Ras ME Castro, I Ferrer, A Cascón, MV Guijarro, M Lleonart, SR Cajal, ... Carcinogenesis 29 (3), 491-499, 2008 | 74 | 2008 |
| Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition C Blanco-Aparicio, AMG Collazo, J Oyarzabal, JF Leal, MI Albarán, ... Cancer letters 300 (2), 145-153, 2011 | 68 | 2011 |
| Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity W Xie, S Forveille, K Iribarren, A Sauvat, L Senovilla, Y Wang, J Humeau, ... Oncoimmunology 8 (11), e1656502, 2019 | 62 | 2019 |
Moshe OrenWeizmann Institute of Science, IsraelVerified email at weizmann.ac.il